Company Performance Metrics
Pharmasset Inc is a clinical-stage pharmaceutical company committed to discovering,
developing and commercializing novel drugs to treat viral infections. Their primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, or HBV, hepatitis C virus, or HCV and human immunodeficiency virus, or HIV. Their research
and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication. They are currently focusing on three product candidates, two of which they are developing themselves and one of which they are developing with a strategic partner:
• Clevudine, for the treatment of HBV, expected to enter Phase 3 registration
clinical trials in the second calendar quarter of 2007;
• R7128, a pro-drug of PSI-6130 for the treatment of HCV, in a Phase 1
clinical trial; and
• Racivir, for the treatment of HIV, in a Phase 2 clinical trial.
